Written answer
Medicinal Products
The Deputy questioned whether limited negotiations over Pluvicto met timely-access and pricing-framework commitments; the Minister referred the matter to the HSE.
2179. Deputy Michael Fitzmaurice asked the Minister for Health her views on whether two commercial negotiation meetings between the HSE and the applicant (details supplied), in the 45 months since the reimbursement application for pluvicto was received in January 2023 is consistent with the commitment to equitable and timely access to new medicines in the National Cancer Strategy; and if it is in line with the targets set by the Framework Agreement on the Supply and Pricing of Medicines. [77167/26]